HIV type 1 genetic diversity and naturally occurring polymorphisms in HIV type 1 Kenyan isolates: Implications for integrase inhibitors

AIDS Research and Human Retroviruses

Volumn 28, Issue 8, 2012, Pages 933-936

  Nyamache, Anthony Kebira ^a,b   Muigai, Anne W T ^b   Nganga, Zipporah ^b   Khamadi, Samoel A ^c  

^a KENYATTA UNIVERSITY   (Kenya)

^b JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY   (Kenya)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; RALTEGRAVIR;

ADOLESCENT; ADULT; AGED; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DATA BASE; FEMALE; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; SAMPLE;

ADOLESCENT; ADULT; AGED; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; KENYA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84864219576     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0122     Document Type: Article

References (15)

1. Robertson DL, Anderson JP, Bradac JA, et al.: HIV-1 nomenclature proposal. Science 2000;288:55-56.
2. Chen JHK, Wong K-H, Chen Z, et al.: Increasing genetic diversity of HIV-1 circulating in Hong Kong. PLoS ONE 2010;5(8):e12198.
3. Derache A, Maiga A-I, Traore O, et al.: Evolution of genetic diversity and drug resistance mutations in HIV-1 among untreated patients from Mali between 2005 and 2006. J Antimicrob Chemother 2008;62:456-463.
4. Brodine SK, Mascola JR, McCutchan FE: Genotypic variation and molecular epidemiology of HIV. Infect Med 1997;14:739-748.
5. Cooper DA, Gatell JM, Rockstroh J, et al.: Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. Abstract of the 14th Conference on Retroviruses and Opportunistic Infection, Abstract 105aLB, 2007.
6. Low A, Prada N, Topper M, et al.: Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors. Antimicrob Agents Chemother 2009;53(10);4275-4282.
7. DeJesus E, Berger D, Markowitz M et al.: Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 ( JTK-303) in treatment-naive and treatment experienced patients. J Acquir Immune Defic Syndr 2006;43:1-5.
8. Engelman A, Mizuuchi K, and Craigie R: HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991;67:1211-1221.
9. Lihana RW, Samoel A, Kizito Lubano K, et al.: HIV Type 1 subtype diversity and drug resistance among HIV type 1- infected Kenyan patients initiating antiretroviral therapy. AIDS Res Hum Retroviruses 2009;25(12):1211-1217.
10. Khamadi SA, Ochieng W, Lihana RW, et al.: HIV type 1 subtypes in circulation in Northern Kenya. AIDS 2005; 21(9):810-814.
11. Kenya Ministry of Health: National AIDS and STD Control Programme (NASCOP). Available at www.aidskenya. org = publications. Accessed April 28, 2009.
12. Arruda LB, Fonseca LA, Duarte AJ, et al.: Genetic diversity on the integrase region of the pol gene among HIV type 1- infected patients naive for integrase inhibitors in Sao Paulo City, Brazil. AIDS Res Hum Retroviruses 2010;26:105-107.
13. Lwembe R, Raphael WL, Ochieng'W, et al.: Changes in the HIV type 1 envelope gene from non-subtype B HIV type 1- infected children in Kenya. AIDS Res Hum Retroviruses 2009;25(3):336-342.
14. Songok EM, Lwembe RM, Kibaya R, et al. Active generation and selection for HIV intersubtype A/D recombinant forms in a coinfected patient in Kenya. AIDS Res Hum Retroviruses 2004;20:255-258.
15. Neilson JR, John GC, Carr JK, et al.: Subtypes of human immunodeficiency virus type 1 and disease stage among women in Nairobi, Kenya. J Virol 1999;73:4393-4403.